Aquino Maria Cecilia

Two-Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma.

The PGI was able to achieve sustained IOP reduction with reduction of medications at 2 years postsurgery in patients with advanced glaucoma.

Three-Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma.

The PGI demonstrated sustained IOP reduction and a reduction of medication burden at 3 years postoperatively.

One-Year Outcomes of Micropulse Cyclophototherapy for Primary Open-angle Glaucoma.

The IOP lowering effect of MPTCP treatment in patients with POAG was found to be modest and transient with a similar medication burden, and definitive glaucoma surgery was needed in a number of patients.

Outcomes of Stent Removal in Eyes With the Paul Glaucoma Implant With Intraluminal 6-0 Polypropylene.

Less than half of the eyes with PGI stented with intraluminal 6-0 polypropylene required stent removal.

Comparison of refractive outcomes after combined cataract and glaucoma surgery: trabeculectomy and glaucoma drainage device implantation.

Apart from a significant deviation in short AL eyes, combined cataract surgery and GDD implantation demonstrated no significant postoperative refractive prediction error.

Clinical Efficacy and Safety of the PAUL Glaucoma Implant: A Systematic Review and Meta-Analysis.

This meta-analysis provides quantitative evidence supporting the clinical efficacy and safety of the PGI in patients with refractory glaucoma.

Glaucoma drainage device exposure in Asian eyes.